NCT05191017View on ClinicalTrials.gov

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

July 31, 2026

Conditions
Prostate CancerProstatic CancerCancer of ProstateCancer of the ProstateProstate NeoplasmCastrate Resistant Prostate CancerCastration Resistant Prostatic CancerCastration Resistant Prostatic Neoplasms
Interventions
DRUG

NUV-422

NUV-422 is an investigational drug for oral dosing.

DRUG

Enzalutamide

Enzalutamide

Trial Locations (3)

17325

Pennsylvania Cancer Specialists and Research Institute, Gettysburg

22031

NEXT Virginia, Fairfax

44718

Gabrail Cancer Center Research, Canton

Sponsors

Lead Sponsor

Nuvation Bio Inc.
All Listed Sponsors
lead

Nuvation Bio Inc.

INDUSTRY